Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,697 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti-PD-1 Immunotherapy in Fibrotic Tumors.
Akiyama T, Yasuda T, Uchihara T, Yasuda-Yoshihara N, Tan BJY, Yonemura A, Semba T, Yamasaki J, Komohara Y, Ohnishi K, Wei F, Fu L, Zhang J, Kitamura F, Yamashita K, Eto K, Iwagami S, Tsukamoto H, Umemoto T, Masuda M, Nagano O, Satou Y, Saya H, Tan P, Baba H, Ishimoto T. Akiyama T, et al. Among authors: masuda m. Cancer Res. 2023 Mar 2;83(5):753-770. doi: 10.1158/0008-5472.CAN-22-1890. Cancer Res. 2023. PMID: 36543251
Extracellular Vesicles from Cancer-Associated Fibroblasts Containing Annexin A6 Induces FAK-YAP Activation by Stabilizing β1 Integrin, Enhancing Drug Resistance.
Uchihara T, Miyake K, Yonemura A, Komohara Y, Itoyama R, Koiwa M, Yasuda T, Arima K, Harada K, Eto K, Hayashi H, Iwatsuki M, Iwagami S, Baba Y, Yoshida N, Yashiro M, Masuda M, Ajani JA, Tan P, Baba H, Ishimoto T. Uchihara T, et al. Among authors: masuda m. Cancer Res. 2020 Aug 15;80(16):3222-3235. doi: 10.1158/0008-5472.CAN-19-3803. Epub 2020 Jun 30. Cancer Res. 2020. PMID: 32605995
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.
Tsuge A, Watanabe S, Kawazoe A, Togashi Y, Itahashi K, Masuda M, Sai A, Takei S, Muraoka H, Ohkubo S, Sugiyama D, Yan Y, Fukuoka S, Doi T, Shitara K, Koyama S, Nishikawa H. Tsuge A, et al. Among authors: masuda m. Cancer Immunol Res. 2024 Nov 27. doi: 10.1158/2326-6066.CIR-24-0713. Online ahead of print. Cancer Immunol Res. 2024. PMID: 39602577
Functional genome screen for therapeutic targets of osteosarcoma.
Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, Shoji A, Shitashige M, Masuda M, Kawai A, Chuman H, Iwamoto Y, Hirohashi S, Yamada T. Yamaguchi U, et al. Among authors: masuda m. Cancer Sci. 2009 Dec;100(12):2268-74. doi: 10.1111/j.1349-7006.2009.01310.x. Epub 2009 Aug 10. Cancer Sci. 2009. PMID: 19725836 Free PMC article.
Emergence of TNIK inhibitors in cancer therapeutics.
Yamada T, Masuda M. Yamada T, et al. Among authors: masuda m. Cancer Sci. 2017 May;108(5):818-823. doi: 10.1111/cas.13203. Epub 2017 Apr 24. Cancer Sci. 2017. PMID: 28208209 Free PMC article. Review.
Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations.
Kaneko S, Takasawa K, Asada K, Shiraishi K, Ikawa N, Machino H, Shinkai N, Matsuda M, Masuda M, Adachi S, Takahashi S, Kobayashi K, Kouno N, Bolatkan A, Komatsu M, Yamada M, Miyake M, Watanabe H, Tateishi A, Mizuno T, Okubo Y, Mukai M, Yoshida T, Yoshida Y, Horinouchi H, Watanabe SI, Ohe Y, Yatabe Y, Saloura V, Kohno T, Hamamoto R. Kaneko S, et al. Among authors: masuda m. Mol Cancer. 2024 Jun 11;23(1):126. doi: 10.1186/s12943-024-02035-6. Mol Cancer. 2024. PMID: 38862995 Free PMC article.
2,697 results